Stock Research for CYTK

CYTK

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CYTK Stock Chart & Research Data

The CYTK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CYTK Due diligence Resources & Stock Charts

The CYTK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYTK Detailed Price Forecast - CNN Money CNN View CYTK Detailed Summary - Google Finance
Yahoo View CYTK Detailed Summary - Yahoo! Finance Zacks View CYTK Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CYTK Trends & Analysis - Trade-Ideas Barrons View CYTK Major Holders - Barrons
NASDAQ View CYTK Call Transcripts - NASDAQ Seeking View CYTK Breaking News & Analysis - Seeking Alpha
Spotlight View CYTK Annual Report - CompanySpotlight.com OTC Report View CYTK OTC Short Report - OTCShortReport.com
TradeKing View CYTK Fundamentals - TradeKing Charts View CYTK SEC Filings - Bar Chart
WSJ View Historical Prices for CYTK - The WSJ Morningstar View Performance/Total Return for CYTK - Morningstar
MarketWatch View the Analyst Estimates for CYTK - MarketWatch CNBC View the Earnings History for CYTK - CNBC
StockMarketWatch View the CYTK Earnings - StockMarketWatch MacroAxis View CYTK Buy or Sell Recommendations - MacroAxis
Bullish View the CYTK Bullish Patterns - American Bulls Short Pains View CYTK Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CYTK Stock Mentions - StockTwits PennyStocks View CYTK Stock Mentions - PennyStockTweets
Twitter View CYTK Stock Mentions - Twitter Invest Hub View CYTK Investment Forum News - Investor Hub
Yahoo View CYTK Stock Mentions - Yahoo! Message Board Seeking Alpha View CYTK Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CYTK - SECform4.com Insider Cow View Insider Transactions for CYTK - Insider Cow
CNBC View CYTK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYTK - OTC Markets
Yahoo View Insider Transactions for CYTK - Yahoo! Finance NASDAQ View Institutional Holdings for CYTK - NASDAQ


Stock Charts

FinViz View CYTK Stock Insight & Charts - FinViz.com StockCharts View CYTK Investment Charts - StockCharts.com
BarChart View CYTK Stock Overview & Charts - BarChart Trading View View CYTK User Generated Charts - Trading View




Latest Financial News for CYTK


This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
Posted on Wednesday April 10, 2024

GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema


Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Posted on Wednesday April 10, 2024

Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstructi


EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
Posted on Tuesday April 09, 2024

Cytokinetics Inc (NASDAQ:CYTK), a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for muscle diseases, has reported an insider sale according to a recent SEC filing.


Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
Posted on Friday April 05, 2024

Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and FunctionSOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical study of aficamten in patients with hypertrophic cardi


Stock Market & Investing Books

Enter a stock symbol to view the stock details.